TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06249763

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High gluten diet
Description: Trial period A: gluten free diet added daily granola bars with 10 g gluten/day (intervention).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten free diet
Description: Trial period B: gluten free diet added daily granola bars with \<1 g gluten/day (placebo).
Study: NCT06176001

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation in groups
Description: Group-based psychoeducation for relatives. Group size: 20-40 relatives. Duration of intervention: six sessions, each two hours long with a 15 minutes break, over a period of 6-10 weeks. The sessions are held by experienced clinicians from the Copenhagen Affective Disorder Clinic, one chief physician and one nurse. Each session focuses on a specific topic, which the clinicians present and discuss using a presentation viewer. The sessions are interactive, and the participants are encouraged to ask questions during the presentations. During each session the participants will have some discussions in smaller groups to reflect on a topics and issues raised during the session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: psychoeducation in groups
Description: Group-based psychoeducation for relatives. Group size: 20-40 relatives. Duration of intervention: six sessions, each two hours long with a 15 minutes break, over a period of 6-10 weeks. The sessions are held by experienced clinicians from the Copenhagen Affective Disorder Clinic, one chief physician and one nurse. Each session focuses on a specific topic, which the clinicians present and discuss using a presentation viewer. The sessions are interactive, and the participants are encouraged to ask questions during the presentations. During each session the participants will have some discussions in smaller groups to reflect on a topics and issues raised during the session.
Study: NCT05754957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milvexian
Description: Milvexian will be administered orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT05739383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Description: Subcutaneous injection in pre-filled syringe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in 1.5ml
Description: Matching placebo in 1.5ml solution for injection
Study: NCT05611307

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid profile
Description: Advanced lipid profile

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid profile
Description: Advanced lipid profile

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid profile
Description: Advanced lipid profile

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary artery assessment
Description: Coronary artery assessment via CT scans

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary artery assessment
Description: Coronary artery assessment via CT scans

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary artery assessment
Description: Coronary artery assessment via CT scans

Intervention type: DIAGNOSTIC_TEST
Intervention: Hormone levels for hypogonadism
Description: Hormone levels for hypogonadism

Intervention type: DIAGNOSTIC_TEST
Intervention: Hormone levels for hypogonadism
Description: Hormone levels for hypogonadism

Intervention type: DIAGNOSTIC_TEST
Intervention: Hormone levels for hypogonadism
Description: Hormone levels for hypogonadism
Study: NCT04540159

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-cytometric analysis
Description: Measuring the level of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 in the intraabdominal ascites

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-cytometric analysis
Description: Measuring the level of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 in the intraabdominal ascites
Study: NCT06360432

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Dietary modification program
Description: Participants will receive an 8-week program consisting of personalized dietary modification program. The dietary modification program is composed of a total of 8 personalized, one-hour face-to-face sessions. Participants will be encouraged to take on a moderate hypocaloric plan that cuts daily energy expenditure to encourage steady weight loss while preserving muscle mass. A protein intake of 1.5 g/kg of body weight per day is recommended. To optimize protein uptake, it's suggested that protein be distributed evenly across meals, aiming for 25-30 g per meal, inclusive of 2.5-2.8 g of leucine. Participants will also receive a guidebook, crafted through the Delphi method, to facilitate the adoption of these dietary modifications in their daily routines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary modification program
Description: Participants will receive an 8-week program consisting of personalized dietary modification program. The dietary modification program is composed of a total of 8 personalized, one-hour face-to-face sessions. Participants will be encouraged to take on a moderate hypocaloric plan that cuts daily energy expenditure to encourage steady weight loss while preserving muscle mass. A protein intake of 1.5 g/kg of body weight per day is recommended. To optimize protein uptake, it's suggested that protein be distributed evenly across meals, aiming for 25-30 g per meal, inclusive of 2.5-2.8 g of leucine. Participants will also receive a guidebook, crafted through the Delphi method, to facilitate the adoption of these dietary modifications in their daily routines.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise training
Description: Participants will receive an 8-week program consisting of exercise training. It entails weekly group sessions, with each lasting an hour for 8 weeks. These sessions, designed for groups of approximately 10, will blend resistance and aerobic workouts to enhance muscle mass and strength while reducing fat in individuals with SO. Each session includes a 10-minute warm-up and cool-down, 20 minutes of resistance training using elastic bands, followed by a 20-minute brisk walking segment. Participants will also receive a YouTube link and a pamphlet describing the exercises, encouraging them to maintain at least 30 minutes of exercise five times a week during and beyond the supervised programme.
Study: NCT06540066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-B3227
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-B3227
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-B3227
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Administered in accordance with relevant local guidelines and/or prescribing information.
Study: NCT05380856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Turning ON the neuromodulator
Description: IPG on

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Turning OFF the neuromodulator
Description: IPG OFF
Study: NCT05210023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NUTRIGENETIC DIET INTERVENTION
Description: Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be established according to certain nutrigenetic recommendations identified in the reference bibliography.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONVENTIONAL DIET INTERVENTION
Description: Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be in accordance with the recommendations made by the WHO (World Health Organization), the AHA (American heart association) and the NOM (Official Mexican Standards) for the treatment of obesity and dyslipidemias.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days.
Study: NCT06543641

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Coronary computed tomography angiography
Description: All patients received coronary computed tomography angiography.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Invasive coronary angiography
Description: According to the study criteria some of the patients received confirmation imaging with invasive coronary angiography.
Study: NCT06434272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early exercise with partial Blood Flow Restriction
Description: The intervention comprises of 12 weeks of blood flow restriction exercise in weeks 1-12 after injury. Three weekly exercise sessions are performed. Six supervised sessions are provided during the 12 weeks.~Blood flow restriction of 80% of the limb occlusion pressure required to fully restrict the arterial blood flow is employed.~The intervention comprises three exercises: Seated leg extension, standing knee flexion, and seated heel-rise performed at home as an adjunct to usual care treatment.~Each exercise is performed in four sets of 30, 15, 15, +1 repetitions, with the fourth set (+1) being as many repetitions as possible.~Pause in between sets is 30 seconds. Pause in between exercises are 120 seconds.~In weeks 13-24, patients in this arm follow usual care treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late exercise with partial Blood Flow Restriction
Description: The intervention comprises of 12 weeks of blood flow restriction exercise in weeks 13-24 after injury. Three weekly exercise sessions are performed. Six supervised sessions are provided during the 12 weeks.~Blood flow restriction of 80% of the limb occlusion pressure required to fully restrict the arterial blood flow is employed.~The intervention comprises three exercises: Leg press in machine, heel-rise in machine, knee flexion in machine performed at training facilities as an adjunct to usual care treatment. If facilities are unavailable, three home-based exercises will be provided.~Each exercise, regardless of study arm, is performed in four sets of 30, 15, 15, +1 repetitions, with the fourth set (+1) being as many repetitions as possible.~In weeks 1-12, patients in this arm follow usual care treatment.
Study: NCT05968014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG vs FICB
Description: pericapsular nerve group block versus fascia iliaca compartment block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG vs FICB
Description: pericapsular nerve group block versus fascia iliaca compartment block
Study: NCT04987632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole, an aromatase inhibitor, is considered to be the first-line drug for ovulation induction in PCOS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole, an aromatase inhibitor, is considered to be the first-line drug for ovulation induction in PCOS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Domestic and foreign studies suggest that acupuncture and electroacupuncture can improve the menstrual cycle of PCOS and reduce the level of total testosterone; Acupuncture can regulate glucose homeostasis by stimulating the autonomic nervous system of PCOS patients. Our previous studies and a large number of literatures have proved that acupuncture can improve insulin resistance in PCOS, and acupuncture can improve the pregnancy rate in PCOS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Governor vessel moxibustion
Description: It can warm the kidney, promote digestion and absorption, remove dampness and promote blood circulation
Study: NCT05878392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone filling materials
Description: the buccal jumping gap was packed using PRF in group 1 the buccal jumping gap was packed using xenograft in group 2 the buccal jumping gap was packed using Alloplastic β-tricalcium phosphate in group 3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone filling materials
Description: the buccal jumping gap was packed using PRF in group 1 the buccal jumping gap was packed using xenograft in group 2 the buccal jumping gap was packed using Alloplastic β-tricalcium phosphate in group 3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone filling materials
Description: the buccal jumping gap was packed using PRF in group 1 the buccal jumping gap was packed using xenograft in group 2 the buccal jumping gap was packed using Alloplastic β-tricalcium phosphate in group 3
Study: NCT04954313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subgingival chlorhexidine irrigation
Description: The dose information for the Chlorhexidine gluconate will be 0.12% with 1 mL in each dental pocket at a frequency of every 3 months for the duration of the study (18 months).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental Supplies
Description: Subjects in the Treatment Group will receive a commercial electric toothbrush (Colgate hum), toothpaste (Colgate Renewal), mouthwash (Colgate Zero), proxabrush (Colgate), and floss (Colgate Palmolive brand) to be used at home along with instructions on their use. Brush heads for the electric toothbrush will be replaced every 3 months and products (toothpaste, mouthwash, proxabrush, and floss) will be replenished at every site visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Periodonal Treatment
Description: Initial periodontal treatment consisting of a pre-procedural rinse and scaling \& root planing (SRP).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodonal Treatment
Description: Initial periodontal treatment consisting of a pre-procedural rinse and scaling \& root planing (SRP).
Study: NCT04876456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
Study: NCT06360432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants will receive an 8-week program consisting of exercise training. It entails weekly group sessions, with each lasting an hour for 8 weeks. These sessions, designed for groups of approximately 10, will blend resistance and aerobic workouts to enhance muscle mass and strength while reducing fat in individuals with SO. Each session includes a 10-minute warm-up and cool-down, 20 minutes of resistance training using elastic bands, followed by a 20-minute brisk walking segment. Participants will also receive a YouTube link and a pamphlet describing the exercises, encouraging them to maintain at least 30 minutes of exercise five times a week during and beyond the supervised programme.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EatWellLog App
Description: Only participants in the M-health group will be instructed to use the EatWellLog app for daily diet self-management. This App supports participants with SO by providing a structured approach to managing a diet that encourages steady weight loss while maintaining muscle mass, in line with current nutritional recommendations for this demographic. The EatWellLog App has the following features: i) tracking participants' dietary habits by logging meals and snacks from a food list, ii) personalized online coaching and reminders by a multidisciplinary healthcare team, iii) participation of family caregivers through an interactive messaging function, iv) accessing health information via multiple channels, including animations, an at-a-glance display, and a reminder, and v) utilization of game elements, such as educational animations and video games to disseminate health and nutritional information related to SO.
Study: NCT06061523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Oral Tablet
Study: NCT04865601

Intervention type: OTHER
Intervention: resectomy of the colon
Description: The patient scheduled for colon resectomy are included in the study

Intervention type: OTHER
Intervention: resectomy of the colon
Description: The patient scheduled for colon resectomy are included in the study
Study: NCT06545747

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DCE-MRI based split-course hypo-RT
Description: Tumor delineation will be based on DCE-MRI and CT. MRI help define the tumor boundary. Different radiation doses will be delivered based on the Ktrans value of the tumor area on DCE-MRI.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT based split-course hypo-RT
Description: Tumor delineation will be based on CT. The total dose for both the first and boost courses of hypo-RT to the tumor area will be constant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemotherapy
Description: Concurrent Chemotherapy consists of weekly albumin-bound paclitaxel 50mg/m2, d1 plus cisplatin 25mg/m2，d1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: Concurrent Chemotherapy consists of weekly albumin-bound paclitaxel 50mg/m2, d1 plus cisplatin 25mg/m2，d1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consolidative immunotherapy
Description: Consolidative PD-1/PD-L1 inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidative immunotherapy
Description: Consolidative PD-1/PD-L1 inhibitors
Study: NCT06483581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: M-TAPA block with bupivacaine 25%
Description: Following sterile conditions for bilateral M-TAPA block application, the transducer will be inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle will be created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip will be placed just below the chondrium and saline (5 ml) will be injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine will be administered for each group for a total of 40 ml of local anesthetic. Blocks will be applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose will be applied to the contralateral side for each group of M-TAPA patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAP block with bupivacaine 25%
Description: After the necessary sterilization conditions established, the linear ultrasound probe will be placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum will be identified. As the tip of the 80 mm sonovisible needle passes through the muscular layers and fascia, the needle will be advanced in a controlled manner. After receiving the click sensation (passage of the fascia of the internal oblique muscle), the location of the needle will be fixed and 20 ml of 0.25% bupivacaine will be injected between internal oblique and transversus abdominis muscles. Same procedure will be performed to the other site. (40 ml local anesthetics in total)
Study: NCT04865601

Intervention type: OTHER
Intervention: resectomy of the colon
Description: The patient scheduled for colon resectomy are included in the study

Intervention type: OTHER
Intervention: resectomy of the colon
Description: The patient scheduled for colon resectomy are included in the study

Intervention type: OTHER
Intervention: resectomy of the colon
Description: The patient scheduled for colon resectomy are included in the study
Study: NCT04948450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Progressive resistance training (PRT) for the physical intervention will be provided at the nursing home for 45 minutes twice a week. The sessions will be organized in groups (10 patients/ group) and supervised by 2 physiotherapists. Within each small group (maximum 10), participants will follow the program tailored to their individual functioning level, with constant oversight by trainers.~People with dementia and care staff will be instructed to follow the prescribed PRT exercises for the rest of the week. Subjects will be encouraged to exercise daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation intervention
Description: The study subjects will receive cognitive intervention based on Cognitive Stimulation Therapy with rehabilitation experts. The intervention involves 14 sessions of themed activities, which typically run twice weekly. The sessions will be organized in groups (10 patients/ group).~People with dementia and their care staff will be instructed on how to practice the various activities at their nursing home for the rest of the week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social intervention
Description: Social intervention will be combined with physical and cognitive interventions through doing these in a group, playing games during exercises (dancing, throwing ball to each other) or doing cognitive stimulation therapy in a group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management of metabolic and vascular risk factors
Description: Study physicians will assess the risk of developing new chronic diseases, change in blood pressure, weight and BMI, and hip and waist circumference, blood test (glucose, lipid parameters, fasting glucose, and HbA1C if the person with dementia has diabetes) at 3 and 6 months.~Participants in the intervention group will be provided with information on the importance of reducing risk factors, guidance on lifestyle changes and prescribing treatment if necessary by cardiologists and endocrinologists. The target for blood pressure is less than 120/90 mmHg and the target for HbA1c is less than 7.5 %.
Study: NCT06038513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transnasal Thermal Regulating Device
Description: Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 24 hours